Cookies Policy
The website need some cookies and similar means to function. If you permit us, we will use those means to collect data on your visits for aggregated statistics to improve our service. Find out More
Accept Reject
  • Menu
About

About

Daniel Vasconcelos was born in Espinho (Portugal) in 1988 and he is a Registered Tech Transfer Professional (RTTP). Currently, he is the Head of INESC TEC’s Technology Licensing Office (TLO) and his main goal is to boost the societal impact of the R&D results. Leading a team of three tech managers, Daniel paves the way for the development and commercialization of deep tech solutions, bridging the gap between the Lab and the Market. Daniel oversees a portfolio of 33 active patent families in ICT, medical technology, and instrumentation fields. He is also a consultant for INESC TEC spin-offs. He is also a European IP Helpdesk Ambassador for Portugal, a pro-bono first-line IP support service for SMEs and partners of European projects. Daniel is also a member of renowned organizations that foster Intellectual Property and Knowledge Transfer, such as the ASTP, the TTO Circle, the PATLIB network and the i3PM. He is an invited IP and Business Strategy speaker, including software and open-source licensing. Daniel is an invited professor at Faculdade de Engenharia da Universidade do Porto for medical technology development (Biodesign) and Management courses. He holds a PhD in Biomedical Sciences, an MSc in Bioengineering, and an MSc in Innovation Economics and Management, all from U.Porto, and has extensive advanced training by the EPO, CEIPI, WIPO, and Harvard Law School.

Details

Details

  • Name

    Daniel Marques Vasconcelos
  • Role

    Service Manager
  • Since

    15th February 2017
014
Publications

2020

Osteoclasts degrade fibrinogen scaffolds and induce mesenchymal stem/stromal osteogenic differentiation

Authors
Almeida, AR; Bessa Goncalves, M; Vasconcelos, DM; Barbosa, MA; Santos, SG;

Publication
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A

Abstract
Fibrinogen (Fg) is a pro-inflammatory protein with pro-healing properties. Previous work showed that fibrinogen 3D scaffolds (Fg-3D) promote bone regeneration, but the cellular players were not identified. Osteoclasts are bone resorbing cells that promote bone remodeling in close crosstalk with osteoblasts. Herein, the capacity of osteoclasts differentiated on Fg-3D to degrade the scaffolds and promote osteoblast differentiation was evaluated in vitro. Fg-3D scaffolds were prepared by freeze-drying and osteoclasts were differentiated from primary human peripheral blood monocytes. Results obtained showed osteoclasts expressing the enzymes cathepsin K and tartrate resistant acid phosphatase colonizing Fg-3D scaffolds. Osteoclasts were able to significantly degrade Fg-3D, reducing the scaffold's area, and increasing D-dimer concentration, a Fg degradation product, in their culture media. Osteoclast conditioned media from the first week of differentiation promoted significantly stronger human primary mesenchymal stem/stromal cell (MSC) osteogenic differentiation, evaluated by alkaline phosphatase activity. Moreover, week 1 osteoclast conditioned media promoted earlier MSC osteogenic differentiation, than chemical osteogenesis inductors. TGF-beta 1 was found increased in osteoclast conditioned media from week 1, when compared to week 3 of differentiation. Taken together, our results suggest that osteoclasts are able to differentiate and degrade Fg-3D, producing factors like TGF-beta 1 that promote MSC osteogenic differentiation.

2020

Pneuma: Entrepreneurial science in the fight against the COVID-19 pandemic - a tale of industrialisation and international cooperation

Authors
Mendonça J.M.; Cruz N.; Vasconcelos D.; Sá-Couto C.; Moreira A.P.; Costa P.; Mendonça H.; Pereira A.; Naimi Z.; Miranda V.;

Publication
Journal of Innovation Management

Abstract
When the COVID-19 pandemic hits Portugal in early March 2020, medical doctors, engineers and researchers, with the encouragement of the Northern Region Health Administration, teamed up to develop and build, locally and in a short time, a ventilator that might eventually be used in extreme emergency situations in the hospitals of northern Portugal. This letter tells you the story of Pneuma, a low-cost emergency ventilator designed and built under harsh isolation constraints, that gave birth to derivative designs in Brazil and Morocco, has been industrialized with 200 units being produced, and is now looking forward to the certification as a medical device that will possibly support a go-tomarket launch. Open intellectual property (IP), multi disciplinarity teamwork, fast prototyping and product engineering have shortened to a few months an otherwise quite longer idea-to-product route, clearly demonstrating that when scientific and engineering knowledge hold hands great challenges can be successfully faced.

2018

Chitosan porous 3D scaffolds embedded with resolvin D1 to improve in vivo bone healing

Authors
Vasconcelos, DP; Costa, M; Neves, N; Teixeira, JH; Vasconcelos, DM; Santos, SG; Aguas, AP; Barbosa, MA; Barbosa, JN;

Publication
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A

Abstract
The aim of this study was to investigate the effect chitosan (Ch) porous 3D scaffolds embedded with resolvin D1 (RvD1), an endogenous pro-resolving lipid mediator, on bone tissue healing. These scaffolds previous developed by us have demonstrated to have immunomodulatory properties namely in the modulation of the macrophage inflammatory phenotypic profile in an in vivo model of inflammation. Herein, results obtained in an in vivo rat femoral defect model demonstrated that two months after Ch+RvD1 scaffolds implantation, an increase in new bone formation, in bone trabecular thickness, and in collagen type I and Coll I/Coll III ratio were observed. These results suggest that Ch scaffolds embedded with RvD1 were able to lead to the formation of new bone with improvement of trabecular thickness. This study shows that the presence of RvD1 in the acute phase of the inflammatory response to the implanted biomaterial had a positive role in the subsequent bone tissue repair, thus demonstrating the importance of innovative approaches for the control of immune responses to biomedical implants in the design of advanced strategies for regenerative medicine. (c) 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 1626-1633, 2018.

2018

Profiling the circulating miRnome reveals a temporal regulation of the bone injury response

Authors
Silva, AM; Almeida, MI; Teixeira, JH; Ivan, C; Oliveira, J; Vasconcelos, D; Neves, N; Ribeiro Machado, C; Cunha, C; Barbosa, MA; Calin, GA; Santos, SG;

Publication
THERANOSTICS

Abstract
Bone injury healing is an orchestrated process that starts with an inflammatory phase followed by repair and remodelling of the bone defect. The initial inflammation is characterized by local changes in immune cell populations and molecular mediators, including microRNAs (miRNAs). However, the systemic response to bone injury remains largely uncharacterized. Thus, this study aimed to profile the changes in the plasma miRnome after bone injury and determine its biological implications. Methods: A rat model of femoral bone defect was used, and animals were evaluated at days 3 and 14 after injury. Non-operated (NO) and sham operated animals were used as controls. Blood and spleen were collected and peripheral blood mononuclear cells (PBMC) and plasma were separated. Plasma miRnome was determined by RT-qPCR array and bioinformatics Ingenuity pathway analysis (IPA) was performed. Proliferation of bone marrow mesenchymal stem/stromal cells (MSC) was evaluated by Ki67 staining and high-throughput cell imaging. Candidate miRNAs were evaluated in splenocytes by RT-qPCR, and proteins found in the IPA analysis were analysed in splenocytes and PBMC by Western blot. Results: Bone injury resulted in timely controlled changes to the miRNA expression profile in plasma. At day 3 there was a major down-regulation of miRNA levels, which was partially recovered by day 14 post-injury. Interestingly, bone injury led to a significant up-regulation of let-7a, let-7d and miR-21 in plasma and splenocytes at day 14 relative to day 3 after bone injury, but not in sham operated animals. IPA predicted that most miRNAs temporally affected were involved in cellular development, proliferation and movement. MSC proliferation was analysed and found significantly increased in response to plasma of animals days 3 and 14 post-injury, but not from NO animals. Moreover, IPA predicted that miRNA processing proteins Ago2 and Dicer were specifically inhibited at day 3 post-injury, with Ago2 becoming activated at day 14. Protein levels of Ago2 and Dicer in splenocytes were increased at day 14 relative to day 3 post-bone injury and NO animals, while in PBMC, levels were reduced at day 3 (albeit Dicer was not significant) and remained low at day 14. Ephrin receptor B6 followed the same tendency as Ago2 and Dicer, while Smad2/3 was significantly decreased in splenocytes from day 14 relative to NO and day 3 post-bone injury animals. Conclusion: Results show a systemic miRNA response to bone injury that is regulated in time and is related to inflammation resolution and the start of bone repair/regeneration, unravelling candidate miRNAs to be used as biomarkers in the monitoring of healthy bone healing and as therapeutic targets for the development of improved bone regeneration therapies.

2018

Interplay between sympathetic nervous system and inflammation in aseptic loosening of hip joint replacement

Authors
Ribeiro da Silva, M; Vasconcelos, DM; Alencastre, IS; Oliveira, MJ; Linhares, D; Neves, N; Costa, G; Henrique, R; Lamghari, M; Alves, CJ;

Publication
SCIENTIFIC REPORTS

Abstract
Inflammation is a common symptom in joint disorders such as rheumatoid arthritis, osteoarthritis (OA) and implant aseptic loosening (AL). The sympathetic nervous system is well known to play a critical role in regulating inflammatory conditions, and imbalanced sympathetic activity has been observed in rheumatoid arthritis. In AL it is not clear whether the sympathetic nervous system is altered. In this study we evaluated the systemic and local profile of neuroimmune molecules involved in the interplay between the sympathetic nervous system and the periprosthetic inflammation in hip AL. Our results showed that periprosthetic inflammation does not trigger a systemic response of the sympathetic nervous system, but is mirrored rather by the impairment of the sympathetic activity locally in the hip joint. Moreover, macrophages were identified as key players in the local regulation of inflammation by the sympathetic nervous system in a process that is implant debris-dependent and entails the reduction of both adrenergic and Neuropetide Y (NPY)-ergic activity. Additionally, our results showed a downregulation of semaphorin 3A (SEMA3A) that may be part of the mechanism sustaining the periprosthetic inflammation. Overall, the local sympathetic nervous system emerges as a putative target to mitigate the inflammatory response to debris release and extending the lifespan of orthopedic implants.